Type 1 diabetes (T1D) is an autoimmune disorder characterized by the specific destruction of insulin-producing pancreatic ...
Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), an emerging biotechnology company focused on developing cell-based therapies for diabetes and age-related disorders, today announced ...
The EPITA Symposium brings together global scientists, clinicians, and industry leaders to advance biological therapies for diabetes, including islet transplantation and beta cell replacement. EPITA ...
Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, Jan. /CNW/ — USA News Group News Commentary – Global capital is officially rotating into “Longevity Infrastructure” which is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results